Compare ARAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARAI | GDTC |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | Singapore |
| Employees | 51 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.4M |
| IPO Year | 2024 | 2021 |
| Metric | ARAI | GDTC |
|---|---|---|
| Price | $0.15 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 16.4K |
| Earning Date | 11-13-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,250.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,900.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.68 |
| 52 Week High | $6.86 | $3.68 |
| Indicator | ARAI | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 26.95 | 47.73 |
| Support Level | N/A | $0.74 |
| Resistance Level | $0.29 | $1.07 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 4.83 | 38.53 |
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.